Zachery D Schultz
Overview
Explore the profile of Zachery D Schultz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
80
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao S, Sperger J, Schehr J, McKay R, Emamekhoo H, Singh A, et al.
J Clin Invest
. 2022 Nov;
132(21).
PMID: 36317634
BackgroundNeuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management of metastatic prostate cancer.MethodsWe performed analytical validation of a Circulating Tumor Cell (CTC)...
2.
Bootsma M, McKay R, Emamekhoo H, Bade R, Schehr J, Mannino M, et al.
J Clin Oncol
. 2022 May;
40(31):3633-3641.
PMID: 35617646
Purpose: Liquid biopsies in metastatic renal cell carcinoma (mRCC) provide a unique approach to understand the molecular basis of treatment response and resistance. This is particularly important in the context...
3.
Schehr J, Sethakorn N, Schultz Z, Hernandez C, Bade R, Eyzaguirre D, et al.
Biomark Res
. 2022 Apr;
10(1):26.
PMID: 35468853
Introduction: PD-L1 expression in non-small cell lung cancer (NSCLC) predicts response to immune checkpoint blockade, however is an imperfect biomarker given tumor heterogeneity, and the antigen presentation pathway requiring other...
4.
Pezzi H, Guckenberger D, Schehr J, Rothbauer J, Stahlfeld C, Singh A, et al.
Lab Chip
. 2018 Oct;
18(22):3446-3458.
PMID: 30334061
Rare cell populations provide a patient-centric tool to monitor disease treatment, response, and resistance. However, understanding rare cells is a complex problem, which requires cell isolation/purification and downstream molecular interrogation...
5.
Schehr J, Schultz Z, Warrick J, Guckenberger D, Pezzi H, Sperger J, et al.
PLoS One
. 2016 Jul;
11(7):e0159397.
PMID: 27459545
Background: Expression of programmed-death ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) is typically evaluated through invasive biopsies; however, recent advances in the identification of circulating tumor cells (CTCs)...